The year in cardiovascular medicine 2021: diabetes and metabolic disorders

Author:

Cosentino Francesco1ORCID,Bhatt Deepak L.2ORCID,Marx Nikolaus3ORCID,Verma Subodh4567

Affiliation:

1. Cardiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm SE171 77, Sweden

2. Department of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA

3. Department of Internal Medicine, University Hospital Aachen, RWTH Aachen University, Aachen, Germany

4. Department of Pharmacology and Toxicology, University of Toronto, 27 King’s College Circle, Toronto, ON, Canada M5S 3J3

5. Division of Cardiovascular Surgery, St Michael’s Hospital, 30 Bond Street, Toronto, ON, Canada M5B 1W8

6. Institute of Medical Sciences, University of Toronto, 27 King’s College Circle, Toronto, ON, Canada M5S 3J3

7. Department of Surgery, University of Toronto, 27 King’s College Circle, Toronto, ON, Canada M5S 3J3

Abstract

Abstract In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3